October 2021

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

2021-10-15T13:30:54-04:00October 15th, 2021|Whitepapers|

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

September 2021

July 2021

June 2021

The New Era in ADA Assays

2021-10-05T08:32:34-04:00June 7th, 2021|Webinars|

Anti-Drug Antibody (ADA) assays such as ligand-based assays are critical to assess the clinical efficacy and safety of a biological drug. ADA assays rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived (e.g., rabbits) pooled polyclonal antibodies (pAb) [...]

Polyclonal Antibody Sequencing with Only Proteomics

2021-10-05T08:27:24-04:00June 1st, 2021|Webinars|

Landing on the Moon with Mass Spectrometry: Polyclonal Sequencing with Only Proteomics Presented by Anthony Stajduhar, Director of International Business Development, Rapid Novor Over the past 5 years Rapid Novor has perfected monoclonal antibody sequencing, and is now sequencing mAbs from polyclonal mixtures using REpAb®.  After successfully launching their proteogenomics based [...]